Literature DB >> 11458003

Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not.

P D Drew1, M T Moss2, T J Pasieka3, C Grose3, W J Harris2,1, A J R Porter1.   

Abstract

Murine monoclonal antibody 206 (MAb mu206) binds to gH, the varicella-zoster virus (VZV) fusogen, neutralizing the virus in vitro in the absence of complement and inhibiting cell-to-cell spread and egress of VZV in cultured cells. We have humanized this antibody to generate MAb hu206 by complementarity determining region grafting. MAb hu206 retained binding and in vitro neutralizing activity, as well as cross-reactivity with ten different VZV strains. Single-chain antibody fragments (scAb) derived from MAb hu206 were produced in Escherichia coli. These scAb retained the binding properties of the whole antibody. However, monomeric scAb exhibited markedly reduced neutralizing activity compared to the bivalent parental MAb hu206. Shortening the peptide linker joining the V(H) to the V(kappa) domain from 14 to 5 or even 0 residues encouraged multimerization and increased neutralizing efficacy. The fact that Fab fragments enzymatically generated from whole MAb hu206 lost their neutralizing potency lent support to the proposal that valency is important for VZV neutralization at this epitope.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11458003     DOI: 10.1099/0022-1317-82-8-1959

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B.

Authors:  Tina M Cairns; Juan Fontana; Zhen-Yu Huang; J Charles Whitbeck; Doina Atanasiu; Samhita Rao; Spencer S Shelly; Huan Lou; Manuel Ponce de Leon; Alasdair C Steven; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.

Authors:  Adalbert Krawczyk; Jürgen Krauss; Anna M Eis-Hübinger; Martin P Däumer; Robert Schwarzenbacher; Ulf Dittmer; Karl E Schneweis; Dirk Jäger; Michael Roggendorf; Michaela A E Arndt
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

3.  Expression and characterization of an enantioselective antigen-binding fragment directed against α-amino acids.

Authors:  Pierre P Eleniste; Heike Hofstetter; Oliver Hofstetter
Journal:  Protein Expr Purif       Date:  2013-07-01       Impact factor: 1.650

4.  Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H.

Authors:  Yasushi Akahori; Kazuhiro Suzuki; Tohru Daikoku; Masae Iwai; Yoshihiro Yoshida; Yoshizo Asano; Yoshikazu Kurosawa; Kimiyasu Shiraki
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

5.  Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model.

Authors:  Susan E Vleck; Stefan L Oliver; Mike Reichelt; Jaya Rajamani; Leigh Zerboni; Carol Jones; James Zehnder; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

6.  Reduction of enterotoxin induced fluid accumulation in ileal loops of neonatal calves with anti-F5 fimbriae recombinant antibody.

Authors:  Alfredo Sahagun-Ruiz; Leticia V Velazquez; Shoba Bhaskaran; Chris M Jay; E Morales-Salinas; Keerti Rathore; Gale G Wagner; Suryakant D Waghela
Journal:  Vet Res Commun       Date:  2015-10-31       Impact factor: 2.459

7.  Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.

Authors:  Nicole L Sullivan; Morgan A Reuter-Monslow; Janet Sei; Eberhard Durr; Carl W Davis; Cathy Chang; Megan McCausland; Andreas Wieland; David Krah; Nadine Rouphael; Aneesh K Mehta; Mark J Mulligan; Bali Pulendran; Rafi Ahmed; Kalpit A Vora
Journal:  J Virol       Date:  2018-06-29       Impact factor: 6.549

8.  The cytoplasmic domain of varicella-zoster virus glycoprotein H regulates syncytia formation and skin pathogenesis.

Authors:  Edward Yang; Ann M Arvin; Stefan L Oliver
Journal:  PLoS Pathog       Date:  2014-05-29       Impact factor: 6.823

Review 9.  Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

Authors:  Leonard Both; Ashley C Banyard; Craig van Dolleweerd; Edward Wright; Julian K-C Ma; Anthony R Fooks
Journal:  Vaccine       Date:  2013-01-29       Impact factor: 3.641

Review 10.  Monoclonal antibodies for prophylactic and therapeutic use against viral infections.

Authors:  Leonard Both; Ashley C Banyard; Craig van Dolleweerd; Edward Wright; Julian K-C Ma; Anthony R Fooks
Journal:  Pediatr Pol       Date:  2013-08-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.